Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Raul A. Urrutia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1640-6780; OpenAlex author ID A5013280795; NIH RePORTER profile ID 1893199. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 7)
Trials
0
Grants
1
Labs led
2
Collaborators
98
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper, 1 grant · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 32

  1. PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. Co-author DOI 10.3389/fcell.2026.1748541↗
  2. Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. Co-author DOI 10.3390/epigenomes10010019↗
  3. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102421↗
  4. Understanding the heterogeneity of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102479↗
  5. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. Co-author DOI 10.7150/ijbs.102132↗
  6. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.freeradbiomed.2024.01.003↗
  7. EZH2 deletion does not affect acinar regeneration but restricts progression to pancreatic cancer in mice. Co-author DOI 10.1172/jci.insight.173746↗
  8. Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer Last author DOI 10.21037/jgo-24-326↗
  9. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Co-author DOI 10.1016/j.ebiom.2023.104602↗
  10. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  11. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321397↗
  12. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Co-author DOI 10.1016/j.ebiom.2021.103332↗
  13. Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. Last author DOI 10.3389/fonc.2021.606820↗
  14. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. Co-author DOI 10.1158/1541-7786.mcr-19-0490↗
  15. Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine. Last author DOI 10.1038/s41467-019-11812-7↗
  16. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cells8111453↗
  17. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Last author DOI 10.1038/s41467-018-04383-6↗
  18. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  19. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  20. The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. Co-author DOI 10.1038/cddis.2016.202↗
  21. The promise of epigenomic therapeutics in pancreatic cancer. Last author DOI 10.2217/epi-2015-0016↗
  22. The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. First author DOI 10.1016/j.suc.2015.05.011↗
  23. IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0896↗
  24. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Co-author DOI 10.1038/onc.2013.68↗
  25. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  26. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. Co-author DOI 10.1172/jci76037↗
  27. Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. Last author DOI 10.1016/j.ajpath.2012.12.004↗
  28. NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells. Co-author DOI 10.4161/auto.22258↗
  29. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. Co-author DOI 10.1002/emmm.201201255↗
  30. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. Co-author DOI 10.1172/jci60144↗
  31. Polycomb and the emerging epigenetics of pancreatic cancer. Last author DOI 10.1007/s12029-011-9262-4↗
  32. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. Co-author DOI 10.1074/jbc.m110.197533↗

Grants 1

  1. Epigenomic Regulation in Pancreatic Cell Growth R01DK052913↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gwen Alyce Lomberk · 25 shared papers, 1 shared grant, 2011–2026 · strength 3.67
  2. Juan Iovanna · 20 shared papers, 2012–2026 · strength 2.21
  3. Nelson Dusetti · 12 shared papers, 2016–2025 · strength 1.67
  4. Michael T. Zimmermann · 5 shared papers, 2021–2026 · strength 1.15
  5. Nicolas Alejandro Fraunhoffer · 5 shared papers, 2021–2025 · strength 1.05
  6. Gareth Pollin · 3 shared papers, 2024–2026 · strength 0.87
  7. Analía Meilerman Abuelafia · 3 shared papers, 2022–2025 · strength 0.56
  8. Rémy Nicolle · 5 shared papers, 2017–2023 · strength 0.46
  9. Omer Hany Miligy Elmadbouh · 2 shared papers, 2024–2025 · strength 0.42
  10. Stephen Jacob Pandol · 2 shared papers, 2024–2025 · strength 0.42
  11. Arsen Osipov · 2 shared papers, 2024–2025 · strength 0.42
  12. Mouad Edderkaoui · 2 shared papers, 2024–2025 · strength 0.42
  13. Odile Gayet · 5 shared papers, 2017–2022 · strength 0.42
  14. Patricia Santofimia‐Castaño · 2 shared papers, 2019–2025 · strength 0.33
  15. Daniel Grasso · 3 shared papers, 2013–2025 · strength 0.32
  16. Julie Roques · 3 shared papers, 2017–2022 · strength 0.32
  17. Abdessamad El Kaoutari · 2 shared papers, 2021–2024 · strength 0.29
  18. Eduardo Chuluyán · 2 shared papers, 2015–2025 · strength 0.29
  19. Madeline M. Dzikowski · 1 shared paper, 2026 · strength 0.29
  20. Céline Loncle · 6 shared papers, 2012–2017 · strength 0.26
  21. Matías Estarás · 1 shared paper, 2025 · strength 0.25
  22. Neil A. Bhowmick · 1 shared paper, 2025 · strength 0.21
  23. Yan Ou · 1 shared paper, 2025 · strength 0.21
  24. Dina Hauptschein · 1 shared paper, 2025 · strength 0.21
  25. Ramachandran Murali · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.